Teplizumab
TzieldUniProt P07766 · 3D model
Drag to rotate. Scroll or pinch to zoom.
An antibody that calms down the immune cells attacking the pancreas, buying time before type 1 diabetes fully develops.
How it works
Teplizumab is a lab-made antibody that attaches to a protein called CD3 on T cells — the immune cells that mistakenly attack the insulin-producing cells in the pancreas in type 1 diabetes. Rather than killing these T cells, it temporarily reprograms them: it dials down their attack signal, encourages more of the immune system's own regulatory cells, and pushes the aggressive T cells toward a worn-out, less active state, slowing the immune attack on the pancreas.
What it’s used for
Tzield is approved to push back the point at which early-stage (Stage 2) type 1 diabetes turns into full-blown (Stage 3) disease requiring insulin therapy, in people age 1 and up. It's also approved to slow the loss of the body's own insulin production in children and teens recently diagnosed with Stage 3 type 1 diabetes. In the trial behind its approval, a single two-week course of treatment delayed diagnosis by about two years on average compared to placebo.
- Mechanism
- CD3-directed T-cell modulator (monoclonal antibody)
- Drug class
- Monoclonal antibody
- Therapeutic area
- Metabolic / Diabetes
The first drug that delays a disease before it fully starts
Type 1 diabetes doesn't appear overnight — there's often a silent stage beforehand where the immune system is already attacking the pancreas, detectable by blood tests, before a person has any symptoms. Teplizumab was the first drug ever approved to intervene at that earlier stage: a two-week course of infusions calms down the immune attack enough to buy patients real time, an extra two years on average, before they need insulin. It doesn't cure or fully prevent the disease, but it was the first drug of any kind shown to delay a disease's onset in this way, not just treat it once it arrives.
Pivotal trial
A TrialNet randomized, placebo-controlled trial in relatives of type 1 diabetes patients with stage 2 (pre-symptomatic, autoantibody-positive) disease, in which a single course of teplizumab delayed median time to clinical diagnosis by about two years versus placebo.